Expiration Date: July 29, 2017
Media: Internet - based
This two-part activity will focus on the evolution of precision medicine through the current and future use of next-generation sequencing in patient identification, therapy selection, and ongoing management.
CME/CE Activity Table of Contents
- Next-Generation Sequencing (NGS) and Proteomic Testing: An Introduction and Overview
- Next-Generation Sequencing (NGS) versus Proteomic Testing of Tumor Samples: A Comparison
- Next-Generation Sequencing and Proteomics: Where Are We Today?
- The Present-Day Advantages of Genomic Tumor Data … and Future Advantages of Proteomic Tumor Data
- Proteomic Platforms: An Overview
- The National Cancer Moonshot: How Can Tumor Testing Analyses Support This?
- Molecular Testing: Addressing the Challenges of Treating Patients with Cancer
Instructions For This Activity & Receiving Credit
This educational activity is primarily directed toward medical oncologists who treat patients with cancer. It is designed to meet the needs of community oncologists. Additionally, fellows, nurses, nurse practitioners, physician assistants, and other healthcare professionals (HCPs) involved in the treatment of cancer may also participate.
At the conclusion of this activity, you should be better prepared to:
- Provide a historical perspective on the development of next-generation sequencing and how molecular diagnostic technologies have advanced in recent decades
- Describe next-generation sequencing and protein analyses including any current applications to cancer treatment
- Explain the key differences between genomic sequencing and proteomic testing analyses
- Determine the potential clinical impact of evolving tumor testing technologies in the context of the National Cancer Moonshot
Faculty, Staff, and Planners' Disclosures
William J. Gradishar, MD, FASCO, FACP
Betsy Bramsen Professor of Breast Oncology
Director, Maggie Daley Center for Women's Cancer Care
Robert H. Lurie Comprehensive Cancer Center of Feinberg School of Medicine
Disclosure: No relevant financial relationships with commercial interests.
Philip C. Mack, PhD
Associate Adjunct Professor
Director of Molecular Pharmacology
UC Davis Comprehensive Cancer Center
Disclosure: Grant/Research Support: Boehringer Ingelheim and Lilly Oncology; Consultant: MolecularMD and Apton.
The following individuals have no relevant financial relationships with commercial interests:
The staff of PER®, LLC.
Disclosure Policy and Resolution of Conflicts of Interest (COI)
It is the policy of Physicians' Education Resource®, LLC, (PER®) to ensure fair balance, independence, objectivity, and scientific rigor in all of our CME/CE activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as a part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
Off-Label Disclosure and Disclaimer
This CME/CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient's medical condition.
The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of Physicians' Education Resource®, LLC, or any of the companies that provided commercial support for this activity.
Hardware And Software Requirements
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)
Minimum System Requirements (Windows)
- A Pentium-based PC or compatible computer
- At least 64MB of RAM
- Windows 95/98/NT/ME/2000/XP/Vista system software
- Screen resolution of 1024 x 786 or larger recommended
- PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise